Financials

UCB on track

Today, UCB is much better positioned for the future than a year ago, with increased critical mass significant enough to advance a rich pipeline and launch our new products. UCB's new leadership team is now aligned and executing our plan to become the next generation biopharma leader building on an even stronger talent pool.

2007 was an important year for UCB - especially with two new product launches in the USA, four regulatory filings in the USA and the EU. We achieved an impressive amount of R&D milestones, although we did not meet all our R&D goals. we am particularly proud that more and more patients with severe diseases, especially with epilepsy and movement disorders, benefit from UCB's medicines.

The underlying positive financial performance, were in line with previous years' all time high performance and supported by our successful integration.

Solid revenue of EUR3.6 billion with net sales of EUR3.2 billion, were driven by outstanding Keppra® sales of more than EUR1 billion, Xyzal® sales growing to EUR168 million, excellent performance of Neupro® with sales of EUR52 million, supported by successful US launch.

Underlying profitability, recurring EBITDA, of EUR741 million was supported by successful integration of Schwarz Pharma with EUR166 million synergies realised in 2007.

Net profit reached EUR160 million, reflecting the acquisition related financial expenses, in addition to substantial restructuring expenses as well as additional investments for the launch of new products.